Q-omics provides the consensus-scored SLFNL1 profile across patient tissues and cancer cell-line models. SLFNL1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SLFNL1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, SLFNL1 RNA expression shows 19,793 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where SLFNL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLFNL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLFNL1 survival associations across molecular data types. SLFNL1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLFNL1 RNA expression–survival associations across cancer types. High SLFNL1 expression shows unfavorable associations in MESO, BLCA, COAD, LGG and ACC, but favorable associations in HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SLFNL1 RNA expression.
This table summarizes SLFNL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLFNL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLFNL1 shows lower tumor expression in LUAD, LUSC and THCA and higher tumor expression in KIRC, HNSC and COAD. The KIRC box plot shows higher SLFNL1 RNA expression in tumor versus normal tissue (log2 FC = +0.249, t-test p < 0.001).
This table shows molecular features associated with SLFNL1 in patient tissues and cancer cell lines. In patient samples, SLFNL1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLFNL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
